molecules of the month


oral LRRK2 kinase inhibitor

Ph. I completed in Parkinson’s Disease

HTS, SBDD, and CNS-focused opt.

Sci. Transl. Med.

Denali Therapeutics Inc., South San Francisco, CA

DNL201 Chemical Structure oral LRRK2 kinase inhibitor - Denali Therapeutics Inc., South San Francisco, CA
6 mins read

Context. DNL201 (Denali Therapeutics) is an oral, CNS-penetrating, ATP-competitive leucine-rich repeat kinase 2 (LRRK2) inhibitor being developed for Parkinson’s disease (PD). PD remains incurable; current treatment options only alleviate disease symptoms and do not prevent progression. Due to its well known involvement in familial and even sporadic/idiopathic PD, LRRK2, particularly the G2019S variant, has been a hotly pursued target in the last decade, with at least a dozen promising agents having been reported (e.g., Merck’s MLi-2 and “compound 24” which we have previously featured). However, clinical advancement of these molecules has been hampered by concerns about potential lung toxicity. Although a previous preclinical study evaluating pulmonary toxicity in macaques seemed to validate these concerns, data provided by Denali scientists in…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: